Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with multiple myeloma based on standard diagnostic guidelines
- Depending on which treatment group applies to you: you have had 1 to 3 previous treatments for multiple myeloma (including specific drug types called proteasome inhibitors and immunomodulatory drugs), OR you have never been treated for multiple myeloma before, OR you have had at least 1 or 2 prior treatments including specific drugs (confirm with trial site which group applies to you)
- You weigh at least 40 kilograms (about 88 pounds)
- You are able to carry out basic daily activities, either fully or with some limitations (this is measured on a standard scale called ECOG — confirm with trial site)
- Your multiple myeloma can be measured through blood tests, urine tests, or certain types of scans at the time of screening
Who may not be able to join:
- You have a serious active infection (such as a viral, bacterial, or fungal infection) that currently requires treatment
- You have an autoimmune disease that required treatment with immune-suppressing medicines within the last 6 months
- You have had a serious heart condition recently, such as a heart attack, unstable chest pain, or heart bypass surgery within the last 6 months, or you have moderate-to-severe heart failure
- You have recently received certain cancer treatments, including targeted therapies, chemotherapy, antibody treatments, or radiation, within specific time periods before joining (confirm with trial site for exact timeframes)
- You received a type of cell therapy called CAR-T or similar gene-modified cell therapy within the last 90 days
- You had a donor stem cell transplant within the last 6 months, or your own stem cells were transplanted within the last 12 weeks
- You still have side effects from previous cancer treatment that have not mostly cleared up (with some exceptions such as hair loss or mild nerve problems)
- You have previously been treated with a type of therapy that redirects immune cells called T cells (CD3-redirecting therapy)
- You need extra oxygen to breathe properly on an ongoing basis
- You have HIV, active hepatitis B, or active hepatitis C
- You have had a stroke or seizure within the last 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1: Number of Participants with Dose-limiting Toxicity (DLT); Number of Participants with Adverse Events (AEs) by Severity; Number of Participants with Clinically Significant Laboratory Abnormalities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.